Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 10/20 | 0.58 |
| ▸ | HTR1B | P28222 | 6/20 | 0.56 |
| ▸ | MPO | P05164 | 5/20 | 0.46 |
| ▸ | HTR1A | P08908 | 5/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22643951 | 0.88 | HTR1D (0.75) | HTR1DHTR1BMPOHTR1AHTR2A | |
| SCHEMBL8507874 | 0.82 | HTR1D (0.80) | HTR1DHTR1BMPOHTR2A | |
| SCHEMBL20077509 | 0.80 | HTR1D (0.44) | HTR1DHTR1BHTR2A | |
| SCHEMBL23030468 | 0.78 | HTR1D (0.43) | HTR1DHTR1BHTR2A | |
| SCHEMBL8506249 | 0.78 | HTR1D (0.54) | HTR1DHTR1BMPOHTR1AHTR2A | |
| SCHEMBL8506246 | 0.78 | SLC6A4 (0.62) | HTR1DHTR1B | |
| SCHEMBL9210389 | 0.76 | HTR1D (0.51) | HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL8344495 | 0.76 | HTR1D (0.73) | HTR1DHTR1BMPOHTR1AHTR2A | |
| SCHEMBL13964396 | 0.76 | HTR1A (0.66) | HTR1DHTR1BMPOHTR1AHTR2A | |
| SCHEMBL12881234 | 0.75 | HTR1B (0.56) | HTR1DHTR1BHTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | HTR1D 1537/4885HTR1B 597/4885MPO 2699/4885 |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | HTR1D 1651/4885HTR1B 551/4885MPO 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.